ZeSS: A Prospective Observational Safety Study of Patients with BRAFV600 Mutation-positive Unresectable or Metastatic Melanoma Treated with Vemurafenib (Zelboraf®)

21/12/2012
31/03/2024
EU PAS number:
EUPAS3125
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Study results
Study results

GP28492 CSR_Abstract_Redacted

English (725.79 KB - PDF) View document
Study report
Other information